CTI BioPharma Corp (NASDAQ:CTIC) shares shot up 1.7% during mid-day trading on Thursday . The stock traded as high as $3.02 and last traded at $2.97. 219,442 shares traded hands during mid-day trading, a decline of 2% from the average session volume of 222,851 shares. The stock had previously closed at $3.02.
Several research firms have issued reports on CTIC. ValuEngine cut CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Zacks Investment Research raised CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Wednesday, December 27th.
The stock has a market cap of $121.17, a price-to-earnings ratio of -2.53 and a beta of 0.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.19.
An institutional investor recently bought a new position in CTI BioPharma stock. OxFORD Asset Management LLP purchased a new stake in CTI BioPharma Corp (NASDAQ:CTIC) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,211 shares of the biopharmaceutical company’s stock, valued at approximately $164,000. OxFORD Asset Management LLP owned approximately 0.12% of CTI BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 42.81% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/08/cti-biopharma-ctic-shares-up-1-7.html.
CTI BioPharma Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.